2seventy bio stock.

The stock currently has a share float of 103.43%. 2seventy bio Inc stock is held by 225 institutions, with Kynam Capital Management, LP being the largest institutional investor. By Sep 29, 2023, it held 11.76% of the shares, which is about 5.95 million shares worth $10.75 million.

2seventy bio stock. Things To Know About 2seventy bio stock.

Item 7.01 Regulation FD Disclosure. 2seventy bio, Inc. (the "Company") from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of its current presentation is being furnished herewith as Exhibit 99.1 to this Current …Company profile page for 2seventy bio Inc including stock price, company news, press releases, executives, board members, and contact informationIn today’s digital age, having a short bio about yourself is more important than ever. Whether you are a professional looking to make a lasting impression or an aspiring entrepreneur building your personal brand, a well-crafted short bio ca...TSVT Stock 12 Months Forecast. $8.20. (322.68% Upside) Based on 7 Wall Street analysts offering 12 month price targets for 2seventy bio in the last 3 months. The average price target is $8.20 with a high forecast of $20.00 and a low forecast of $2.00. The average price target represents a 322.68% change from the last price of $1.94. CAPITAL STOCK. The total number of shares of capital stock which the Corporation shall have authority to issue is Two Hundred Ten Million (210,000,000), of ...

Apr 28, 2023 · 2Seventy Bio Inc’s ( TSVT) price is currently down 6.76% so far this month. During the month of April, 2Seventy Bio Inc’s stock price has reached a high of $10.35 and a low of $8.25. Over the last year, 2Seventy Bio Inc has hit prices as high as $18.88 and as low as $8.25. Year to date, 2Seventy Bio Inc’s stock is down 62.9%. During the last session, 2seventy bio Inc (NASDAQ:TSVT)’s traded shares were 1.54 million, with the beta value of the company hitting 1.19. At the end of the trading day, the stock’s price was $1.83, reflecting an intraday loss of -4.69% or -$0.09. The 52-week high for the TSVT share is $16.17, that puts it down -783.61 from that peak ...

2seventy bio, Inc. (Nasdaq: TSVT) today announced the presentation of four abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 2-6, 2023 in Chicago, Illinois and six abstracts at the European Hematology Association (EHA) Congress, taking place in Frankfurt, Germany from June 8-11, 2023.

2seventy bio began trading on the Nasdaq on Thursday under the symbol "TSVTV." By market close, shares were trading at $26.65 each, growth of more than 115%. The new company has a market cap of ...In a report released yesterday, Daina Graybosch from Leerink Partners maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a price target of $5.00. Daina Graybosch has given ...2seventy bio Reports Fourth Quarter and Full Year 2022 Financial ...This oncology business has been set up as an independent entity under the name 2seventy bio, Inc. TSVT. Shares of 2seventy bio started trading on the NASDAQ with effect from Nov 5, 2021.Stock analysis for 2seventy bio Inc (TSVTV:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Nov 16, 2023 · 2seventy Bio reports Q3 EPS ($1.40), consensus ($1.03) 2seventy Bio downgraded to Market Perform from Outperform at Leerink 2seventy Bio initiated with a Buy at Citi

2seventy bio, Inc. (TSVT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2023. This widely-known consensus ...

ABECMA generated approximately $150M U.S. revenue in 2021, equally shared by 2seventy bio and Bristol Myers Squibb; anticipate continued ABECMA growth in 2022 with $250-300M U.S. revenue. bbT369 IND cleared - program tests three layers of innovation in B-NHL; achieved goal of two new INDs submitted and cleared by FDA in …2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023. CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a preclinical $15 million milestone as part of the joint …CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jan. 9, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT) announced today key corporate milestones and financial outlook for 2023. “2022 was the launch year of 2seventy bio and we made important progress establishing the fundamentals of our business,” said Nick Leschly, chief kairos officer.The analysts in late October downgraded 2seventy bio shares to market perform from outperform and slashed their price target on the stock to $7 from $29, saying any upside in the shares from an ...Find the latest dividend history for 2seventy bio, Inc. Common Stock (TSVT) at Nasdaq.com.2seventy bio and BMS share equally in all profits and losses related to development, manufacturing, and commercialization of Abecma in the U.S. 2seventy reported collaborative arrangement revenue ...

2seventy bio, Inc. Stock price Equities TSVT US9013841070 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar Company …2seventy bio, Inc. (Nasdaq: TSVT), today announced a restructuring of its business operations and research and development model to significantly reduce costs while supporting the execution of a prioritized plan for the long-term growth of the company. “2seventy’s mission remains the same: to unleash the power of the T-cell and develop …Initial MAGE-A4 T-cell collaboration program set to enter clinic ahead of schedule by end of 2023 Companies plan to add programs in oncology and autoimmune disease to collaboration CAMBRIDGE, Mass. & SHANGHAI, China --(BUSINESS WIRE)--Sep. 12, 2023-- 2seventy bio, Inc .٦ جمادى الأولى ١٤٤٥ هـ ... By Colin Kellaher Shares of 2seventy bio fell more than 10% Monday after the biotechnology company's efforts to win expanded U.S. approval ...Nov 17, 2023 · Citi analyst Samantha Semenkow has maintained their bullish stance on TSVT stock, giving a Buy rating on November 14. Samantha Semenkow has given her Buy rating to 2seventy bio due to a ...

Nov 10, 2023 · Investor Contact. Elizabeth Pingpank, Senior Director, Investor Relations. 860-463-0469. [email protected]. The Investor Relations website contains information about 2seventy bio's business for stockholders, potential investors, and financial analysts. With a price-to-sales (or "P/S") ratio of 5x 2seventy bio, Inc. ( NASDAQ:TSVT) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United ...

Nick Leschly. https://www.2seventybio.com. 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of …The analysts in late October downgraded 2seventy bio shares to market perform from outperform and slashed their price target on the stock to $7 from $29, saying any upside in the shares from an ...By Colin Kellaher . A U.S. Food and Drug Administration decision on the approval of earlier use of the Abecma gene therapy from Bristol Myers Squibb and 2seventy bio has been pushed back after the agency opted to hold an advisory committee meeting to review data supporting the application.Dec 1, 2023 · 2seventy bio last issued its earnings data on August 14th, 2023. The reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.21. The company earned $36.05 million during the quarter, compared to analyst estimates of $31.81 million. 2seventy bio has generated ($3.91) earnings per share over the ... 2seventy bio Inc. on Friday said it inked an expanded collaboration with fellow biotechnology company Regeneron Pharmaceuticals Inc., including a $20 million equity investment at a rich premium. Cambridge, Mass.-based 2seventy said it sold more than 1.11 million shares to Regeneron at $17.94 apiece, a roughly 86% premium to Thursday's …Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.2Seventy Bio Inc is up 4.98% from its previous closing price of $6.03. During the last market session, 2Seventy Bio Inc’s stock traded between $5.44 and $6.46. Currently, there are 43.47 million shares of 2Seventy Bio Inc stock available for purchase. Unfortunately, 2Seventy Bio Inc’s P/E ratio is not significant enough to use for stock ...Complete 2seventy bio Inc. stock information by Barron's. View real-time TSVT stock price and news, along with industry-best analysis.The U.S. health regulator will not meet its Dec. 16 deadline to decide on the expanded use of Bristol Myers Squibb and partner 2seventy bio's blood cancer therapy …

Real time 2seventy Bio (TSVT) stock price quote, stock graph, news & analysis.

2seventy Bio's strong focus on cell therapy-based combinations for solid tumors positions them as a potential leader in the immuno-oncology market. Recent positive results from the KarMMa-3 study ...

2seventy bio, Inc. (NASDAQ:NASDAQ:TSVT) Q1 2023 Earnings Call Transcript May 3, 2023 4:30 PM ETCompany ParticipantsJenn Snyder - SVP of Corporate...With a price-to-sales (or "P/S") ratio of 5x 2seventy bio, Inc. ( NASDAQ:TSVT) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United ...Nov 10, 2023 · 2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. The estimated net worth of Nicola Heffron is at least $533,308.36 as of February 7th, 2023. Ms. Heffron owns 89,182 shares of 2seventy bio stock worth more than $533,308 as of August 11th. This net worth approximation does not reflect any other investments that Ms. Heffron may own. Learn More about Nicola Heffron's net worth.The Investor Relations website contains information about 2seventy bio's business for stockholders, potential investors, and financial analysts. Real time 2seventy Bio (TSVT) stock price quote, stock graph, news & analysis. ٩ محرم ١٤٤٥ هـ ... Possible Bearish Signals With 2seventy bio Insiders Disposing Stock ... A number of 2seventy bio, Inc. (NASDAQ:TSVT) insiders sold their shares in ...Before we jump into 2Seventy Bio Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background. 2seventy bio, Inc. is a cell and gene therapy company, which is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its …Key Points. Bluebird Bio's shares have dropped like a rock in recent years, and its new price tag makes the stock look more like a buy. The biotech boasts an exciting lineup of gene therapies for ...View 2seventy bio Inc (TSVT) company profile, FAQs, interesting facts, information about industry, sector and employees.This free interactive report on 2seventy bio's balance sheet strength is a great place to start, if you want to investigate the stock further.. A Different Perspective. While 2seventy bio ...

Vertex Pharmaceuticals Inc. (VRTX) The final decision of FDA on Vertex Pharma's Exa-cel in the proposed treatment of severe sickle cell disease is due on …2seventy bio, Inc. (NASDAQ:NASDAQ:TSVT) Q1 2023 Earnings Call Transcript May 3, 2023 4:30 PM ETCompany ParticipantsJenn Snyder - SVP of Corporate...In addition, 2seventy bio intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock at the public offering price, less ...Mar 1, 2023 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2023-- 2seventy bio, Inc. (“2seventy bio”) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at a public offering price of $11.50 per share. Instagram:https://instagram. regional stockmuchael burrybest investment strategy for retireesbest pc crypto wallet 2Seventy Bio Inc Stock Price History. 2Seventy Bio Inc’s price is currently down 8.04% so far this month. During the month of April, 2Seventy Bio Inc’s stock price has reached a high of $10.35 and a low of $9.35. Over the last year, 2Seventy Bio Inc has hit prices as high as $18.88 and as low as $8.44. Year to date, 2Seventy Bio Inc’s ... good stock to day tradebankrupt businesses U.S. STOCKS Kohl's, Bristol-Myers Squibb, 2Seventy Bio. Nov 20, 2023 at 4:26 pm GMT. Eikon search string for individual stock moves: STXBZ. The Day Ahead ...Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect 2seventy bio’s business, particularly those identified in the risk factors discussion in 2seventy bio’s Annual Report on Form 10-K, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on ... pemx Following the latest downgrade, the current consensus, from the six analysts covering 2seventy bio, is for revenues of US$51m in 2022, which would reflect an uneasy 11% reduction in 2seventy bio's ...Stock analysis for 2seventy bio Inc (TSVT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.